Streetbeat News

Analyst Ratings

TXN

Truist Securities analyst William Stein has maintained a Hold rating on Texas Instruments (NASDAQ:TXN) and reduced the price target from $169 to $168.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 2:51 pm

MUR

Piper Sandler analyst Mark Lear has maintained an Overweight rating on Murphy Oil (NYSE:MUR) but has reduced the price target from $56 to $50.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 2:51 pm

ISRG

Truist Securities analyst Richard Newitter has reaffirmed a Buy rating on Intuitive Surgical (NASDAQ:ISRG) and increased the price target from $390 to $435.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 2:50 pm

MRO

Piper Sandler analyst Mark Lear has maintained an Overweight rating on Marathon Oil (NYSE:MRO) but has reduced the price target from $34 to $32.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 2:49 pm

CFB

Keefe, Bruyette & Woods analyst Brady Gailey has maintained an Outperform rating on CrossFirst Bankshares (NASDAQ:CFB) and increased the price target from $18 to $20.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 2:49 pm

ELS

Truist Securities analyst Anthony Hau has maintained a Hold rating on Equity Lifestyle Properties (NYSE:ELS) and lowered the price target from $73 to $72.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 2:48 pm

ELS

Truist Securities analyst Anthony Hau has maintained a Hold rating on Equity Lifestyle Properties (NYSE:ELS) but has reduced the price target from $73 to $72.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 2:48 pm

MGY

Piper Sandler analyst Mark Lear has maintained an Overweight rating on Magnolia Oil & Gas (NYSE:MGY) but reduced the price target from $30 to $29.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 2:46 pm

PLUG

B. Riley Securities analyst Christopher Souther has maintained a Buy rating on Plug Power (NASDAQ:PLUG) but has reduced the price target from $18 to $8.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 2:44 pm

MDGL

Piper Sandler analyst Yasmeen Rahimi has maintained an Overweight rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) and increased the price target from $305 to $336.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 2:42 pm